Abstract
Since late 2019, a pandemic caused by SARS-CoV-2, a highly contagious coronavirus, has jeopardized human and public health. Neurodegeneration and structural brain diseases produce dementia, which is developing rapidly. Strong evidence of COVID-19 brain abnormalities as neurotrophic viruses impair neurological systems. Neuron and glial cell degeneration can affect nerve transmission and brain function. Damage to these brain components raises dementia risk. Multiple studies linked SARS-CoV-2 to dementia. This manuscript contains selective data. This study aims to review the findings and suggest strategies to improve SARS-Covid dementia management. The study makes use of medical research databases like Google Scholar, PubMed, Medline, and Embase. Furthermore, information is also collected by recognized health organizations and government agencies. COVID-19 can produce neuropsychological deficits, agitation, confusion, inattention, and disorientation. Thus, SARS can worsen dementia and neurodegeneration. This article summarizes COVID-19's effects on dementia patients from several sources. The focus on existing treatments for affected patients ties the two.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
